Bengaluru: Medtech startup Remidio has unveiled Neubo 130 , an AI-powered retinal imaging device designed to diagnose neonatal retinal conditions such as Retinopathy of Prematurity (ROP).

The Neubo 130 combines advanced optical engineering with edge AI to assist clinicians in real-time ROP detection — even in low-connectivity settings. The system delivers consistent peripheral detail and panoramic retinal views by using an auto-montage feature that stitches multiple gazes into a single, composite image.

“The launch of Neubo 130 marks a major step forward in neonatal eye care ,” said Dr. Anand Sivaraman, CEO, Remidio.

“This platform is our bet on certainty, reframing ROP from a resource problem to an engineering solution. By enabling dependable, on-the-spot decisions at the bed

See Full Page